Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145125 | 0.94 | GPBAR1 (0.64) | GPBAR1RAB9AMAPTCYP3A4CYP2C9 | |
| SCHEMBL3150856 | 0.89 | GPBAR1 (0.61) | GPBAR1RAB9ACYP3A4CYP2C9POLB | |
| SCHEMBL3142750 | 0.89 | GPBAR1 (0.74) | GPBAR1ALDH1A1RAB9AMAPTCYP3A4 | |
| SCHEMBL3145544 | 0.88 | GPBAR1 (0.60) | GPBAR1ALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL3150474 | 0.87 | GPBAR1 (0.63) | GPBAR1RAB9AMEN1KMT2ACYP3A4 | |
| SCHEMBL3142383 | 0.86 | GPBAR1 (0.65) | GPBAR1CYP3A4CYP2C9 | |
| SCHEMBL3141314 | 0.85 | GPBAR1 (0.60) | GPBAR1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL3137865 | 0.84 | GPBAR1 (0.63) | GPBAR1ALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL3141517 | 0.84 | GPBAR1 (0.63) | GPBAR1ALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL3135605 | 0.83 | GPBAR1 (0.74) | GPBAR1ALDH1A1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | claimed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | GPBAR1, GPR119, GLP1R | GPBAR1 1/4885ALDH1A1 341/4885RAB9A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.